← Back to Screener
Cingulate Inc. Common Stock (CING)
Price$3.60
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)4.30%
Price vs S&P 500 (4W)-27.50%
VGM Score33.01
Market Capitalization$55.23M
All Metrics
Book Value / Share (Quarterly)$1.58
P/TBV (Annual)1.73x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.66
Price vs S&P 500 (YTD)-15.08%
EPS (TTM)$-4.33
10-Day Avg Trading Volume0.63M
EPS Excl Extra (TTM)$-4.33
EPS (Annual)$-4.44
ROI (Annual)-225.48%
Cash / Share (Quarterly)$2.17
ROA (Last FY)-148.94%
EBITD / Share (TTM)$-3.77
ROE (5Y Avg)-445.71%
Cash Flow / Share (Annual)$-2.40
P/B Ratio2.93x
P/B Ratio (Quarterly)3.82x
Net Income / Employee (Annual)$-1,603,600
Net Interest Coverage (TTM)-12.16x
ROA (TTM)-158.55%
EPS Incl Extra (Annual)$-4.44
Current Ratio (Annual)1.16x
Quick Ratio (Quarterly)2.37x
3-Month Avg Trading Volume0.51M
52-Week Price Return4.26%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.01
52-Week High$11.89
EPS Excl Extra (Annual)$-4.44
CapEx CAGR (5Y)-16.52%
26-Week Price Return20.23%
Quick Ratio (Annual)1.07x
13-Week Price Return-35.90%
Total Debt / Equity (Annual)2.97x
Current Ratio (Quarterly)2.55x
Enterprise Value$35.48M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.51
3-Month Return Std Dev119.41%
Net Income / Employee (TTM)$-1,979,600
ROE (Last FY)-894.81%
Net Interest Coverage (Annual)-10.47x
EPS Basic Excl Extra (Annual)$-4.44
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.33x
EPS Incl Extra (TTM)$-4.33
Receivables Turnover (Annual)0.00x
ROI (TTM)-212.08%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.34
Price vs S&P 500 (52W)-23.95%
Year-to-Date Return-4.15%
5-Day Price Return-6.94%
EPS Normalized (Annual)$-4.44
ROA (5Y Avg)-235.97%
Month-to-Date Return-19.22%
Cash Flow / Share (TTM)$-1.52
EBITD / Share (Annual)$-4.00
LT Debt / Equity (Annual)0.46x
ROI (5Y Avg)-194.21%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.33
P/B Ratio (Annual)11.69x
Book Value / Share (Annual)$0.35
Price vs S&P 500 (13W)-45.65%
Beta-0.86x
Revenue / Share (TTM)$0.00
ROE (TTM)-365.16%
52-Week Low$3.20
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.95est. -0.46
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CINGCingulate Inc. Common Stock | — | — | D | $3.60 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Cingulate Inc is a clinical-stage biopharmaceutical company developing treatments using its proprietary precision timed-release drug delivery platform. The company focuses on ADHD and anxiety disorders, where less frequent dosing could improve patient outcomes and medication adherence. Cingulate is also evaluating additional therapeutic applications for its platform technology.